News | April 29, 2008

Minimally Invasive Endograft Outperforms Surgical Repair

April 30, 2008 - A new study indicates that use of the minimally invasive W.L. GORE TAG Thoracic Endoprosthesis to treat descending thoracic aneurysms appears to be superior to open surgical repair in anatomically suitable patients.

Investigator Ellen D. Dillavou, M.D., from the division of vascular surgery at the University of Pittsburgh Medical Center, said this is the first study to look at the long-term (five-year) outcomes of the two procedures. "Our researchers studied outcomes of the TAG endograft after its implantation in 140 patients compared to 94 patients who had similar aneurysms repaired by open surgery, between September 1999 and May 2001, as well as 51 more patients who were added in 2003 after revision of the endograft." The long-term follow-up of the multi-center device trial which took place at centers throughout the United States, is detailed in the May 2008 issue of the Journal of Vascular Surgery.

Follow-up consisted of patient visits, computed tomography scans and X-rays at one and six months, then annually for five years. "Initially and at five years, TAG patients had better results," said Dr. Dillavou. "At five years aneurysm-related mortality was 2.8 percent compared to 11.7 percent in open surgery patients, and major adverse events were 57.9 percent vs. 78.7 percent. Endoleaks in TAG patients decreased from 8.1 percent at one month to 4.3 percent at five years."

There were no aneurysm ruptures reported in either group over the study period and no deaths due to aneurysm-related causes after one year in either group. At five years, secondary procedures in the TAG group were lower (15.0 percent vs. 31.9 percent) and many were managed with a minimally invasive approach. Only five TAG patients underwent major aneurysm-related re-interventions (3.6 percent), including one arch aneurysm repair, one open aneurysm repair and three patients with minimally invasive procedures for endoleaks.

Dr. Dillavou added that at five years, aneurysm sac size decreased in 50 percent of the patients and increased in 19 percent of them, compared to the one-month baseline. Comparison with the modified low-porosity device at two years showed sac increase in 12.9 percent of original vs. 2.9 percent in modified grafts. "Although sac enlargement is concerning, early modified device results indicate this issue may be resolved," said Dr. Dillavou.

"Prior to this report it was not known if minimally invasive repairs would be as durable as traditional open repairs," said Dr. Dillavou. "This study demonstrates that in suitable patients, endovascular repair of thoracic aneurysms has clear and lasting advantages over open aneurysm repair and that the TAG endograft is durable to five years of follow-up. This work confirms that the early advantages of minimally invasive endovascular thoracic aneurysm repair extend to five years of follow-up. TAG patients had fewer deaths and complications from their aneurysms, making this the safest approach for suitable patients."

For more information: www.jvascsurg.org and www.VascularWeb.org


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 β€” A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 β€” Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 β€”Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 β€” Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now